Why the $20 Trillion Industry Needs a Clean Up

The $20 trillion industry of medical and biomedical engineering, in which companies are tasked with developing systems to help patients recover from diseases, is now worth $20.7 trillion.

That’s an increase of nearly 25 percent in just a decade.

The trend is expected to continue as a growing number of technologies and tools for medical and biotechnology, including genetic engineering, are developed.

The industry has exploded in recent years, and the U.S. is poised to be the fastest-growing in the world.

But it is still in its infancy, and its growth is likely to accelerate.

The problem is that there is no shortage of high-tech solutions for medical applications.

And while the industry is in the midst of a “big bang” of new technologies, there is little that is being done to address the shortcomings in the existing medical system.

For example, despite the industry’s focus on improving patient outcomes and improving the quality of life, it has a long way to go in understanding the complexities of the human brain and the way it processes information.

“We need to figure out what the problem is, how it works, what the symptoms are, how you can improve it,” said James H. White, a senior fellow at the National Institute of Health and co-author of a study published last year in the journal NeuroImage.

White said that the next step is to look for commonalities in the human brains of different groups of people.

That would help explain why certain patients have a different experience from those who do not.

“That’s a big piece of it,” White said.

“It is not just a question of being more like a human.

It’s a question about whether people in the brain, for example, have a brain structure that is similar to that of the people in some other part of the brain.”

That would be particularly important, because there is a growing body of evidence that some brain regions have a role in emotion and cognition.

In one recent study, researchers identified a region in the cerebellum of patients with Parkinson’s disease, which is responsible for the motor skills that people can use to navigate a world that is unfamiliar to them.

The cerebellar structure is part of a larger brain structure called the thalamus.

Researchers also found that people with Parkinson syndrome are better at distinguishing emotions and motor responses than healthy people.

This may help explain the fact that people who are better able to control their emotions and react to new situations tend to be better able recover from illnesses.

“People who have better emotional and motor control, they are much more resilient,” White told National Review.

“But they’re also less likely to have a neurological condition like Parkinson’s.”

A similar problem exists with cognitive functions.

The brains of people with mild cognitive impairment, or MCI, are relatively simple, so their ability to process information is impaired.

But the brains of those with Alzheimer’s disease and people with other neurological disorders are complex.

A study published in August by the University of North Carolina at Chapel Hill found that cognitive performance in people with Alzheimer or Parkinson’s is comparable to those of healthy people but worse than that of people who do no more than a little bit of cognitive training.

This suggests that there are cognitive functions that are not well understood and are poorly understood by people who have MCI and Alzheimer’s.

A growing body